Cannara Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024
For the six months, sales was CAD 1.82 million compared to CAD 1.76 million a year ago. Revenue was CAD 39.17 million compared to CAD 23.35 million a year ago. Net loss was CAD 1.34 million compared to CAD 0.615104 million a year ago. Basic loss per share from continuing operations was CAD 0.01 compared to CAD 0.01 a year ago. Diluted loss per share from continuing operations was CAD 0.01 compared to CAD 0.01 a year ago.